TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04095910

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Planet Nutrition program
Description: 1. - Nutritional education sessions: The study team previously worked on the development of a handbook called Planet Nutrition which contains around 26 topics of nutrition and health. Interns from the Nutritional Sciences Degree of the University of Sonora implemented the sessions. 2 classes of 1 hour were given weekly, adding 18 sessions in total, during regular school hours. The program contemplates the establishment of different objectives.~2. - Physical activity: The classes were designed and implemented by interns from the Bachelor of Physical Culture and Sport from the University of Sonora along with a teacher from the study team. 3 weekly sessions of 1 hour were provided. The activities were held on the schoolyard court during normal school hours, independent of the physical activity classes of the school.~3. - Indirect family participation: Six information brochures with different nutrition and health topics were sent to parents.
Study: NCT00577720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risedronate
Description: 50mg delayed release risedronate tablet before breakfast, once a week for 13 weeks
Study: NCT05040061

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SkillJoy Intervention
Description: The savoring treatment consisted of an ecological momentary intervention (EMI) for learning and practicing savoring skills-SkillJoy. SkillJoy prompted participants to attend to positive aspects of the present moment, plan and engage in enjoyable activities, record and reflect on positive experiences, note events that turned out well, and look forward to positive events.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Self-Monitoring Control Intervention
Description: The active self-monitoring control EMI prompted participants to notice and write current thoughts and feelings, plan the day's major activities, remember and write about their daily events, and anticipate upcoming important events.
Study: NCT06387498

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Testicular tissue biopsy and cryopreservation
Description: Surgical Procurement of Testicular Tissue: At early stages of technology development, simple orchiectomy (removal of one entire testicle) may give the best chance of preserving sufficient cells for effective therapy. However, incisional biopsy of up to 25% of tissue from one testis (wedge resection) will also be presented to the patient as an alternative option. The amount of testicular parenchyma removed will be at the discretion of the surgeon.
Study: NCT01575782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine
Description: Daily intake of Chloroquine during radiotherapy
Study: NCT03613779

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: LUS-guided therapy
Description: Lung ultrasound guided therapy; if pulmonary congestion (more or equal than 3 B-lines), high dose (80-120mg PO/day furosemide) will be prescribed until next follow up re-assessment. If no congestion (less than 3 B-lines), low dose (0-40mg PO/day furosemide) will be prescribed until next follow up re-assessment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of care will be provided.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard of care will be provided.
Study: NCT02786459

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ProxiScan
Description: ProxiScan probe will be coupled with ProstaScint (a radioactive tracer) and used to perform imaging to detect small lesions in the pelvis that will otherwise be hard to detect with conventional imaging modalities.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ProxiScan
Description: ProxiScan probe will be coupled with ProstaScint (a radioactive tracer) and used to perform imaging to detect small lesions in the pelvis that will otherwise be hard to detect with conventional imaging modalities.
Study: NCT00397111

Intervention type: DEVICE
Intervention: 7T Magnetic Resonance Imaging scanner
Description: Non-significant risk device used for brain imaging

Intervention type: DEVICE
Intervention: 7T Magnetic Resonance Imaging scanner
Description: Non-significant risk device used for brain imaging
Study: NCT02323321

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Preservation of Hearts for Transplantation
Description: Preserving and Assessing Expanded Criteria Donor Hearts for Transplantation
Study: NCT02786459

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ProxiScan
Description: ProxiScan probe will be coupled with ProstaScint (a radioactive tracer) and used to perform imaging to detect small lesions in the pelvis that will otherwise be hard to detect with conventional imaging modalities.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Used as a comparative to ProxiScan.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Used as a comparative to ProxiScan.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Used as a comparative to ProxiScan.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SPECT-CT
Description: Used as a comparative to ProxiScan.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SPECT-CT
Description: Used as a comparative to ProxiScan.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SPECT-CT
Description: Used as a comparative to ProxiScan.
Study: NCT02019381

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Endocrine Society UL Dosage Vitamin D
Description: Endocrine Upper limit arm will get 10,000IU Vitamin D and 1200mg Calcium

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Institute of Medicine Dosage Vitamin D
Description: IOM arm will get 600 IU Vitamin D and 1,200 mg Calcium

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Calcium
Description: 1200mg of CaCO3 supplementation will be given to each participant in both groups

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Calcium
Description: 1200mg of CaCO3 supplementation will be given to each participant in both groups
Study: NCT00972998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenyephrine
Description: Phenyephrine coated suppositories
Study: NCT03718494

Intervention type: DIAGNOSTIC_TEST
Intervention: Brain Magnetic Resonance Imaging (MRI)
Description: Performed on a single 3T system and sequences will be acquired in a single sitting with an exam time under 45 minutes.

Intervention type: DIAGNOSTIC_TEST
Intervention: Brain Magnetic Resonance Imaging (MRI)
Description: Performed on a single 3T system and sequences will be acquired in a single sitting with an exam time under 45 minutes.

Intervention type: DIAGNOSTIC_TEST
Intervention: F-18 Florbetapir Positron Emission Tomography (PET) Imaging
Description: After a 50-minute uptake period, the patient will be positioned on the scanner bed with instructions to remain motionless. Injection of 10 mCi of 18F-Florbetapir (target dose 370 MBq, range 296 - 444 MBq) given. A helical CT image will be obtained at 50 minutes after injection of 18F-Florbetapir, followed by a 20-minute PET acquisition consisting of four 5-minute dynamic frames.

Intervention type: DIAGNOSTIC_TEST
Intervention: F-18 Florbetapir Positron Emission Tomography (PET) Imaging
Description: After a 50-minute uptake period, the patient will be positioned on the scanner bed with instructions to remain motionless. Injection of 10 mCi of 18F-Florbetapir (target dose 370 MBq, range 296 - 444 MBq) given. A helical CT image will be obtained at 50 minutes after injection of 18F-Florbetapir, followed by a 20-minute PET acquisition consisting of four 5-minute dynamic frames.

Intervention type: DIAGNOSTIC_TEST
Intervention: F-18 AV-1451 Positron Emission Tomography (PET) Imaging
Description: Intravenous bolus injection of approximately 370 MBq (10 mCi) of 18F- AV-1451 (approved under IND 124449). PET/CT image acquisition will include a low dose CT and then a 20-minute PET acquisition starting at 50-60 minutes after injection of 18F-T807 and will be performed as 4, 5-minute frames that will then be summed into one static frame. Serial frames will allow for adjustment in the case of patient motion.

Intervention type: DIAGNOSTIC_TEST
Intervention: F-18 AV-1451 Positron Emission Tomography (PET) Imaging
Description: Intravenous bolus injection of approximately 370 MBq (10 mCi) of 18F- AV-1451 (approved under IND 124449). PET/CT image acquisition will include a low dose CT and then a 20-minute PET acquisition starting at 50-60 minutes after injection of 18F-T807 and will be performed as 4, 5-minute frames that will then be summed into one static frame. Serial frames will allow for adjustment in the case of patient motion.

Intervention type: OTHER
Intervention: Neuropsychological Testing
Description: A comprehensive battery of standardized neuropsychological tests administered by trained personnel.

Intervention type: OTHER
Intervention: Neuropsychological Testing
Description: A comprehensive battery of standardized neuropsychological tests administered by trained personnel.
Study: NCT00692705

Intervention type: DRUG
Group type: OTHER
Intervention: Radioligand (11C)AZD2995
Description: Single dose of i.v solution. 1-2 times for AD patients. Once for healthy volunteers.

Intervention type: DRUG
Group type: OTHER
Intervention: Radioligand (11C)AZD2995
Description: Single dose of i.v solution. 1-2 times for AD patients. Once for healthy volunteers.

Intervention type: DRUG
Group type: OTHER
Intervention: Radioligand (11C)AZD2184
Description: Single dose of i.v solution. Once for AD patients respective healthy volunteers.

Intervention type: DRUG
Group type: OTHER
Intervention: Radioligand (11C)AZD2184
Description: Single dose of i.v solution. Once for AD patients respective healthy volunteers.
Study: NCT05451121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: patient sedation with a propofol (sedative agent) after cardiac surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: patient sedation with dexmedetomidine (selective α2-adrenergic receptor (α2-AR) agonist) after cardiac surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol and dexmedetomidine
Description: Patients sedation with a drug combination: propofol and dexmedetomidine (selective α2-adrenergic receptor (α2-AR) agonist)
Study: NCT01354691

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ladostigil hemitartrate
Description: Final dosage strength of 80mg b.i.d will begin at Day 22 following a 21 day dose escalation phase involving 40mg and 60mg b.i.d dosage strengths. Oral, solid dosage.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ladostigil hemitartrate
Description: Final dosage strength of 80mg b.i.d will begin at Day 22 following a 21 day dose escalation phase involving 40mg and 60mg b.i.d dosage strengths. Oral, solid dosage.
Study: NCT00890968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone Acetonide (TAC) DuraPeel
Description: topical gel; once daily (nightly); total duration: 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo DuraPeel
Description: topical gel; once daily (nightly); total duration: 4 weeks
Study: NCT00723840

Intervention type: OTHER
Intervention: Observational Studies: participants treated according to the real clinical practice.
Description: No intervention was administered to the participants specifically for the purpose this study. Participant could be on any drug therapy.
Study: NCT04182191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenoxicam
Description: After extraction of at least one third molar, 89 patients will be treated with tenoxicam (20 mg once daily for 4 days) for pain control, collect the saliva to be genotyped and phenotyped for CYP2C9 (by PCR) and their post-operative notes (pain, swelling, trismus, temperature) will be analyzed.
Study: NCT04549038

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 12-16 hour nutrition
Description: Cases will receive their nutrition over a period of 12-16 hours, with minimum 8 hours of fasting and maximum 12 hours of fasting. Feeding will begin in morning hours unless otherwise directed by an investigator or registered dietician.
Study: NCT01221233

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular Electrical Stimulation
Description: Neuromuscular Electrical Stimulation (NMES) to the low back muscles (i.e. spinal extensors) will be applied at the parameters previously used in the knee muscles at the maximal tolerable intensity, which results in a full, sustained isometric contraction of the back muscles. Pad placement will be just below the waist line, with 2, 2X2 inch pads, on either side of the spine. Participants will be positioned on their belly with 2 pillows under their stomach to level the spine and secured to a table using a belt that crosses the buttock.~The lumbar stabilization program will include exercises targeting the back muscles in three positions: standing, prone (belly), and quadruped (hands and knees).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Moist Heat
Description: For participants who do not receive NMES, moist heat will be applied for 15 minutes in a position of comfort for the participant.~The lumbar stabilization program will include exercises targeting the back muscles in three positions: standing, prone (belly), and quadruped (hands and knees).
Study: NCT04355117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Each subject will subcutaneously self-administer TEV 48125 at 225 mg/1.5 mL (150 mg/mL) once monthly for a total of 2 doses.
Description: Each subject will subcutaneously self-administer TEV 48125 at 225 mg/1.5 mL (150 mg/mL) once monthly for a total of 2 doses.
Study: NCT03877185

Intervention type: DIAGNOSTIC_TEST
Intervention: Live birth rate
Description: Live Birth Rate and Blastulation Rate according to the protocol of COS

Intervention type: DIAGNOSTIC_TEST
Intervention: Live birth rate
Description: Live Birth Rate and Blastulation Rate according to the protocol of COS
Study: NCT00973908

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VSL#3
Description: Patients will o receive one VSL #3 sachets twice a day for the duration of the antibiotic course and for one week after.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will one placebo sachet twice a day for the duration of the antibiotic course and for one week after.
Study: NCT04446143

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mindfulness meditation
Description: Mindfulness meditation

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness meditation
Description: Mindfulness meditation
Study: NCT00611793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTK787/ZK222584 and Bevacizumab
Description: PTK787/ZK222584 will be administered as a single agent orally on days 1-14 of cycle 1. The day 14 dose of PTK787/ZK222584 will be administered in the outpatient clinic and PK samples will be obtained. On Day 15 the patient will receive the initial dose of IV bevacizumab and PTK787/ZK222584. Bevacizumab will be repeated at 2 week intervals in patients with stable disease or better for four cycles of treatment (16 weeks). After four treatment cycles, only patients with a PR or CR will continue treatment with PTK787/ZK222584 and bevacizumab. Patients with stable disease may continue single agent PTK787/ZK22258 from cycle 5 onward. Protocol treatment will continue until disease progression or intolerable toxicity warrants drug discontinuation.
Study: NCT00546819

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Zoster Vaccine, Live
Description: A single dose of 0.65 ml Zoster Vaccine, Live, injected subcutaneously on Day 1

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: A single dose of 0.65 ml Placebo to ZOSTAVAX™ injected subcutaneously on Day 1.
Study: NCT01294930

Intervention type: OTHER
Intervention: Urine density
Description: measurement of urine color, density and plethysmographic variability index before and during surgery.
Study: NCT00847171

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Patient HAS received prior Trastuzumab within the last two weeks, give Trastuzumab 2 mg/kg weekly on Day -1 for 5 weeks.~Patient has NOT received Trastuzumab within the last two weeks, give On Cycle 1, Day -1 ONLY, Loading dose 4 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Cyclophosphamide 200mg/m2 IV in NS 100ml over 30 minutes on Day -1 ONLY. Note: there are no dose modifications for Cyclophosphamide.
Study: NCT02286791

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Awareness Program
Description: For Mindful Awareness Program, 40-minutes weekly sessions for 12 weeks, followed by 40-minutes monthly for 6 months. The mindful awareness practice techniques to be taught to the elderly include: (1) mindfulness of the senses practice; (2) the body scan practice; (3) walking meditation practice; (4) 'movement nature meant' practice; and (5) visuo-motor limb tasks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education Program
Description: For the Health Education Program, weekly sessions of 40 minutes for 12 weeks, followed by monthly sessions of 40 minutes for 6 months.~Week 1: Diabetes Mellitus Week 2: Hypertension Week 3: Home Safety Week 4: Medications Week 5: Diet Week 6: Depression Week 7: Dementia Week 8: Anxiety Week 9: Sleep Week 10: Exercise Week 11: Coping with bereavement Week 12: Social support
Study: NCT00847171

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry
Description: Samples will be analyzed by flow cytometry using Cell Quest software
Study: NCT04231565

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir alafenamide Fumarate
Description: Patients would receive treatment of oral Tenofovir alafenamide Fumarate（TAF）once per day.
Study: NCT02541201

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Plant sterols-enriched low-fat milk
Description: The study product is a dried partly skimmed milk powder with no more than 12% milk fat (11.4g total fat/100g product) containing unesterified, unhydrogenated plant sterols.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Low-fat milk
Description: The placebo product is a dried partly skimmed milk powder.
Study: NCT01724385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravitreal injection of bevacizumab
Description: intravitreal injection of bevacizumab
Study: NCT01415453

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound Stimulus
Description: Short pulses of focused ultrasound will be directed at spots on the retinal surface.
Study: NCT04695119

Intervention type: OTHER
Intervention: Exposure is septic shock (defined according to Sepsis-III) and standard treatment according to departmental protocols.
Description: Collection of data, biomarker and echocardiography analysis will be centralized and blinded. Assessment of endpoints will be blinded.
Study: NCT04210115

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cisplatin
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5-FU
Description: IV infusion

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: external radiation

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: radiotherapy
Description: external radiation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin
Description: IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: leucovorin
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levoleucovorin
Description: IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: levoleucovorin
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: oxaliplatin
Description: IV infusion
Study: NCT03266640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: viral specific cytotoxic t-lymphocytes
Description: CMV specific CTLs will be collected from HLA matched or mismatched donors and manufactured in a GMP facility and administered to patients with refractory CMV infection.
Study: NCT03850301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XBD173
Description: 7 days treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XBD173
Description: 7 days treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etifoxine
Description: 7 days treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etifoxine
Description: 7 days treatment
Study: NCT02274662

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cultured Thymus Tissue
Description: Subjects receive cultured thymus tissue which is implanted into the quadriceps muscle. Subjects may receive pre and/or post-implantation immunosuppression.~Potential subjects are screened for eligibility. The thymus tissue (from an unrelated donor), the donor, and the donor's mother are screened for safety. Cultured thymus tissue is implanted into the subject's quadriceps muscle under general anesthesia in the operating room. Two to three months post-implantation, if medically stable, subjects may undergo an allograft biopsy. Subjects undergo laboratory testing for approximately one year post-implantation. At year 2 post-implantation, subjects are contacted for data collection.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Draw

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabbit Anti-Thymocyte Globulin and Cyclosporine or Tacrolimus
Description: RATGAM and Cyclosporine or Tacrolimus may be given, depending on the patient. The doses, timing, and trough levels will vary depending on the patient's clinical condition.
Study: NCT00847171

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunoenzyme technique

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Measuring Immune Priming In Vivo By Vaccine Site Biopsies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: skin biopsy to be performed on day 3 and day 7 for cycle 1 and 3 only